Madrigal Pharmaceuticals-Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates

Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of$ 6.94. This compares to loss of $5.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 29.11%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 7.55 per share when it actually produced a loss of $7.10, delivering a surprise of 5.96%.Over the last four quarters, the company ha ...